Affinity maturation is a process of improving antibody affinity and binding interactions to target antigen. This is done naturally in vivo through mechanisms of somatic hypermutation and clonal selection in mammalian B cells but can also be achieved in vitro by artificial mutagenesis introduction and selection.
FCMES-AM (Full Coverage Mammalian Expression System for Affinity Maturation) is Biointron's proprietary platform for antibody affinity maturation. With this strategy, each amino acid in the CDR region will be mutated to the other 17 amino acids (except cysteine and methionine) with theoretically same possibility. The resulting mutants will be expressed in a mammalian system, and ELISA binding assay will be conducted to identify hot spots. Candidates that combine selected mutation hotspots will then be expressed, and their affinity changes will be measured by SPR (surface plasmon resonance) and FC (flow cytometry) to find out affinity matured ones.
Feel free to reach out to our expert team to explore how Biointron can help in improving your antibody's affinity, or other kinds of antibody optimization, to make your antibody robust to better survive drug development procedures.